Literature DB >> 16679957

Newborn screening policy in the United Kingdom & the United States: two different communities of practice.

Christine Patch1.   

Abstract

Newborn screening is a rapidly developing area driven by both technological advances and public pressure. If they are not yet, all nurses working with mothers and children will soon be involved with implementing newborn-screening programs, and it is therefore important that they appreciate both the benefits and potential harms of such programs. In the United Kingdom, policy regarding the implementation of newborn-screening programs is developed at national level, and consideration of the introduction of new tests is subject to a formalized evaluation framework. In the United States, by contrast, each state develops its own screening program. Knowledge of developments in newborn screening in different countries that have diverse types of healthcare systems helps to inform nurses about the totality of healthcare for newborns, and assists them in becoming more knowledgeable about how international standards differ from those in the United States.

Entities:  

Mesh:

Year:  2006        PMID: 16679957     DOI: 10.1097/00005721-200605000-00007

Source DB:  PubMed          Journal:  MCN Am J Matern Child Nurs        ISSN: 0361-929X            Impact factor:   1.412


  3 in total

1.  Quality performance of newborn screening systems: strategies for improvement.

Authors:  D Webster
Journal:  J Inherit Metab Dis       Date:  2007-08-14       Impact factor: 4.982

Review 2.  Insights into National Laboratory Newborn Screening and Future Prospects.

Authors:  Ahmed H Mujamammi
Journal:  Medicina (Kaunas)       Date:  2022-02-11       Impact factor: 2.948

3.  Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000.

Authors:  Frédéric B Piel; Andrew J Tatem; Zhuojie Huang; Sunetra Gupta; Thomas N Williams; David J Weatherall
Journal:  Lancet Glob Health       Date:  2014-02       Impact factor: 26.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.